Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib and Bevacizumab in Solid Tumors
NCT06307249Phase 1Recruiting
- Sponsor
- Lebanese University
- Start
- Feb 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of palbociclib and bevacizumab in solid tumor (4 arms), sponsored by Lebanese University. Primary endpoints: Assessment of Cancer Progression up to 60 months, Identification of Potential Biomarkers and 1 more. Started Feb 2023; status: recruiting.
02
Drugs
palbociclibbevacizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06307249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06307249.